GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 2062-2069

  Jiménez, Amanda ^a   Casamitjana, Roser ^a,b,c   Viaplana Masclans, Judith ^c   Lacy, Antonio ^a,c   Vidal, Josep ^a,b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; EXENDIN[9-39]; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE ACTION; HUMAN; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; REMISSION; ROUX Y ANASTOMOSIS; STOMACH BYPASS; WEIGHT REDUCTION;

C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC BYPASS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 84885469835     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1535     Document Type: Article

References (39)

1. Mingrone G, Panunzi S, De Gaetano A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577-1585
2. Schauer PR, Kashyap SR, Wolski K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-1576
3. DirksenC, JørgensenNB, Bojsen-MøllerKN., et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 2012;55:1890-1901
4. Rubino F, R'bibo SL, del Genio F, Mazumdar M, McGraw TE. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol 2010;6:102-109
5. Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol 2011;301:R15-R27
6. Pories WJ, Swanson MS, MacDonald KG., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-350; discussion 350-352
7. Laferrère B, Heshka S, Wang K., et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30:1709-1716
8. Laferrère B, Teixeira J, McGinty J., et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93:2479-2485
9. Pournaras DJ, Osborne A, Hawkins SC., et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg 2010;252: 966-971
10. Torquati A, Lutfi R, Abumrad N, Richards WO. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg 2005;9:1112-1116; discussion 1117-1118
11. Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity.DiabetesCare 2012;35:1420-1428
12. Dar MS, Chapman WH 3rd, Pender JR., et al. GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)? Obes Surg 2012; 22:1077-1083
13. Deane AM, Nguyen NQ, Stevens JE., et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010;95:215-221
14. Edwards CM, Todd JF, Mahmoudi M., et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48: 86-93
15. Nicolaus M, Brödl J, Linke R, Woerle HJ, Göke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 2011;96:229-236
16. Schirra J, Nicolaus M, Roggel R., et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antropyloro- duodenal motility in humans. Gut 2006;55:243-251
17. Witte AB, Grybäck P, Jacobsson H., et al. Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion. Scand J Gastroenterol 2011;46:428-435
18. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagonlike peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011;60:2308-2314
19. Kindel TL, Yoder SM, Seeley RJ, D'Alessio DA, Tso P. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptormediated mechanism. J Gastrointest Surg 2009;13:1762-1772
20. Morínigo R, Vidal J, Lacy AM, Delgado S, Casamitjana R, Gomis R. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg 2008; 247:270-275
21. Buse JB, Caprio S, Cefalu WT., et al. How do we define cure of diabetes? Diabetes Care 2009;32:2133-2135
22. Vidal J, Nicolau J, Romero F., et al. Longterm effects of Roux-en-Y gastric bypass surgery on plasma glucagon-like peptide-1 and islet function in morbidly obese subjects. J Clin Endocrinol Metab 2009; 94:884-891
23. Romero F, Nicolau J, Flores L., et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc 2012;26:2231-2239
24. Dirksen C, Hansen DL, Madsbad S., et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care 2010;33:375-377
25. Salehi M, Vahl TP, D'Alessio DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 2008;93:4909-4916
26. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993;36:857-862
27. Aaboe K, Krarup T, Madsbad S, Holst JJ. GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab 2008;10:994-1003
28. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008;16:298-305
29. Horowitz M, Collins PJ, Harding PE, Shearman DJ. Gastric emptying after gastric bypass. Int J Obes 1986;10:117-121
30. Morínigo R, Moizé V, Musri M., et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006;91:1735-1740
31. Woerle HJ, Albrecht M, Linke R., et al. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am J Physiol Endocrinol Metab 2008;294:E103-E109
32. Goldfine AB, Mun EC, Devine E., et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007;92:4678-4685
33. Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000;23:807-812
34. Falkén Y,Hellström PM,Holst JJ,Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 2011;96:2227-2235
35. Dunning BE, Gerich JE. The role of alphacell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007;28:253-283
36. Muscelli E, Mari A, Casolaro A., et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340-1348
37. Knop FK, Aaboe K, Vilsbøll T., et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 2012;14:500-510
38. WoerleHJ, Carneiro L, Derani A, Göke B, Schirra J. The role of endogenous incretin secretion as amplifier of glucosestimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 2012;61:2349-2358
39. Ban K, Kim KH, Cho CK., et al. Glucagonlike peptide (GLP)-1(9-36)amide- mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-1531